EP0362278A4 - Autokrine beweglichkeitsfaktoren bei der diagnose und behandlung von krebs. - Google Patents

Autokrine beweglichkeitsfaktoren bei der diagnose und behandlung von krebs.

Info

Publication number
EP0362278A4
EP0362278A4 EP19880905318 EP88905318A EP0362278A4 EP 0362278 A4 EP0362278 A4 EP 0362278A4 EP 19880905318 EP19880905318 EP 19880905318 EP 88905318 A EP88905318 A EP 88905318A EP 0362278 A4 EP0362278 A4 EP 0362278A4
Authority
EP
European Patent Office
Prior art keywords
management
cancer diagnosis
autocrine motility
motility factors
factors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19880905318
Other languages
English (en)
French (fr)
Other versions
EP0362278A1 (de
Inventor
Lance A Liotta
Elliott Schiffmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
US Department of Commerce
Original Assignee
US Department of Health and Human Services
US Department of Commerce
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, US Department of Commerce filed Critical US Department of Health and Human Services
Publication of EP0362278A1 publication Critical patent/EP0362278A1/de
Publication of EP0362278A4 publication Critical patent/EP0362278A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity
EP19880905318 1987-06-05 1988-05-27 Autokrine beweglichkeitsfaktoren bei der diagnose und behandlung von krebs. Withdrawn EP0362278A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5838187A 1987-06-05 1987-06-05
US58381 1998-04-09

Publications (2)

Publication Number Publication Date
EP0362278A1 EP0362278A1 (de) 1990-04-11
EP0362278A4 true EP0362278A4 (de) 1990-05-14

Family

ID=22016462

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19880905318 Withdrawn EP0362278A4 (de) 1987-06-05 1988-05-27 Autokrine beweglichkeitsfaktoren bei der diagnose und behandlung von krebs.

Country Status (6)

Country Link
EP (1) EP0362278A4 (de)
JP (1) JP2851288B2 (de)
AU (1) AU614755B2 (de)
CA (1) CA1310902C (de)
IL (1) IL86577A (de)
WO (1) WO1988009797A1 (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE455946B (sv) * 1986-10-20 1988-08-22 Trion Forskning & Utveckling Nya pertussistoxin-polypeptider och antigener samt testsatser, vacciner och intradermala hudtestkompositioner
US5449753A (en) * 1992-01-17 1995-09-12 The United States Of America As Represented By The Department Of Health And Human Services Autotaxin: motility stimulating protein useful in cancer diagnosis
US5382521A (en) * 1992-07-14 1995-01-17 Michigan Cancer Foundation Method of determining metastatic potential of bladder tumor cells
CA2238257A1 (en) * 1998-05-22 1999-11-22 Universite De Montreal Endocytosis of amf-r and uses thereof in cancer therapy
DE19847107A1 (de) * 1998-10-13 2000-04-20 Herbert Ruebben Verwendung von Pertussistoxin zur Behandlung von Tumorerkrankungen
PL201482B1 (pl) 1998-10-16 2009-04-30 Smithkline Beecham Biolog Sposoby wytwarzania kompozycji szczepionki oraz kompozycja szczepionki
WO2001074897A2 (en) * 2000-04-03 2001-10-11 Curagen Corporation Protein amf-1 to amf-10 and nucleic acids encoding the same
DE602005025342D1 (de) 2004-05-28 2011-01-27 Glaxosmithkline Biolog Sa Impfstoffzusammensetzungen mit virosomen und einem saponin-adjuvans
AU2006226543B2 (en) 2005-03-23 2011-10-06 Glaxosmithkline Biologicals S.A. Use of an influenza virus an oil-in-water emulsion adjuvant to induce CD4 T-cell and/or improved B-memory cell response
GB0519871D0 (en) 2005-09-30 2005-11-09 Secr Defence Immunogenic agents
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
CN101378778B (zh) 2005-12-22 2013-02-06 葛兰素史密丝克莱恩生物有限公司 肺炎球菌多糖缀合物疫苗
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
EA015833B1 (ru) 2006-03-30 2011-12-30 Глаксосмитклайн Байолоджикалс С.А. Иммуногенная композиция
DK2043682T3 (da) 2006-07-17 2014-06-02 Glaxosmithkline Biolog Sa Influenzavaccine
BRPI0715581A2 (pt) 2006-07-18 2013-04-24 Glaxosmithkline Biolog Sa proteÍna de fusço hÍbrida imunogÊnica, composiÇço, uso de uma proteÍna ou uma partÍcula, mÉtodo para tratar um paciente suscetÍvel À infecÇço por plasmàdio, sequÊncia de nucleotÍdeo, hospedeiro, e, processo para a produÇço de proteÍna
US8323664B2 (en) 2006-07-25 2012-12-04 The Secretary Of State For Defence Live vaccine strains of Francisella
SI2086582T1 (sl) 2006-10-12 2013-02-28 Glaxosmithkline Biologicals S.A. Cepivo, ki obsega emulzijo olja v vodi kot adjuvans
BRPI0717219B8 (pt) 2006-10-12 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, e, uso de uma composição imunogênica
PE20090146A1 (es) 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
JP2010531330A (ja) 2007-06-26 2010-09-24 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 肺炎連鎖球菌莢膜多糖コンジュゲートを含むワクチン
EP3118213A1 (de) 2007-12-19 2017-01-18 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Lösliche formen von hendra- und nipah-virus-f-glycoprotein und anwendungen davon
MX2010011412A (es) 2008-04-16 2010-11-12 Glaxosmithkline Biolog Sa Vacuna.
GB0900455D0 (en) 2009-01-13 2009-02-11 Secr Defence Vaccine
GB0901423D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0901411D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
MX2012011189A (es) 2010-03-26 2013-02-07 Glaxosmithkline Biolog Sa Vacuna contra el virus e inmunodeficiencia humana.
GB201009273D0 (en) 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
EP2707025B8 (de) 2011-05-13 2017-08-23 Zoetis Services LLC Immunogene hendra- und nipah-virus-g-glycoprotein-zusammensetzungen
CN103533953A (zh) 2011-05-17 2014-01-22 葛兰素史密丝克莱恩生物有限公司 针对肺炎链球菌的疫苗
GB201119999D0 (en) 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
GB201120000D0 (en) 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
ES2939307T3 (es) 2012-12-05 2023-04-20 Glaxosmithkline Biologicals Sa Composición inmunogénica
CN104436157A (zh) 2013-09-23 2015-03-25 恩金生物有限公司 流感疫苗和治疗
US20160331829A1 (en) 2013-12-16 2016-11-17 Zoetis Services Llc Hendra and nipah virus g glycoprotein immunogenic compositions
EP3160500B1 (de) 2014-06-25 2019-08-21 GlaxoSmithKline Biologicals S.A. Clostridium difficile immunogene zusammensetzung
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
GB201616904D0 (en) 2016-10-05 2016-11-16 Glaxosmithkline Biologicals Sa Vaccine
EP3615061A1 (de) 2017-04-28 2020-03-04 GlaxoSmithKline Biologicals S.A. Impfung
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
US20210162042A1 (en) 2017-05-30 2021-06-03 Glaxosmithkline Biologicals S.A. Novel methods for manufacturing an adjuvant
EP3581201A1 (de) 2018-06-15 2019-12-18 GlaxoSmithKline Biologicals S.A. Escherichia coli o157:h7 polypeptide und verwendungen davon
WO2019245266A1 (ko) * 2018-06-20 2019-12-26 박희성 암 유래 amf를 유효성분으로 함유하는 항암용 조성물
JP2021532764A (ja) 2018-07-31 2021-12-02 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 抗原精製方法
EP3849521A1 (de) 2018-09-14 2021-07-21 Massachusetts Institute Of Technology Nanopartikelimpfstoffadjuvanz und verfahren zur verwendung davon
EP3886901A1 (de) 2018-11-29 2021-10-06 GlaxoSmithKline Biologicals S.A. Verfahren zur herstellung eines adjuvans
CA3133985A1 (en) 2019-03-19 2020-09-24 The Uab Research Foundation Saponin-based vaccine adjuvants
EP3777884A1 (de) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogene zusammensetzung
WO2021048081A1 (en) 2019-09-09 2021-03-18 Glaxosmithkline Biologicals Sa Immunotherapeutic compositions
BR112022008761A2 (pt) 2019-11-22 2022-07-26 Glaxosmithkline Biologicals Sa Dosagem e administração de uma vacina de glicoconjugado de sacarídeo
US20230045642A1 (en) 2019-12-19 2023-02-09 Glaxosmithkline Biologicals Sa S. aureus antigens and compositions thereof
US20230277657A1 (en) 2020-05-05 2023-09-07 Glaxosmithkline Biologicals Sa Microfluidic mixing device and methods of use
WO2022029024A1 (en) 2020-08-03 2022-02-10 Glaxosmithkline Biologicals Sa Truncated fusobacterium nucleatum fusobacterium adhesin a (fada) protein and immunogenic compositios thereof
TW202214294A (zh) 2020-09-30 2022-04-16 美商碩騰服務公司 具有ｈｙａＣ及ｎａｎＰ缺失之新穎多殺性巴斯德氏菌株及疫苗
IL303334A (en) 2020-12-02 2023-07-01 Glaxosmithkline Biologicals Sa The perfect fimh by a donor strand
WO2023020993A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020992A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020994A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
US20230190920A1 (en) 2021-12-19 2023-06-22 Massachusetts Institute Of Technology Compositions and methods for long-lasting germinal center responses to a priming immunization
WO2023175454A1 (en) 2022-03-14 2023-09-21 Pfizer Inc. Methods for producing an adjuvant

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 102, 1985, page 195, abstract no. 216406j, Columbus, Ohio, US; F.C. PATTERSON et al.: "The effect of ionophores and related agents on the induction of doming in a rat mammary epithelial cell line", & J. CELL. PHYSIOL. 1985, 123(1), 89-100 *
NATURE, vol. 272, 1978, pages 725-727, Macmillan Journals Ltd; J.A. MELERO et al.: "Possible transcriptional control of three polypeptides which accumulate in a temperature-sensitive mamalian cell line"Complete article *
See also references of WO8809797A1 *

Also Published As

Publication number Publication date
AU614755B2 (en) 1991-09-12
AU1803488A (en) 1989-01-04
EP0362278A1 (de) 1990-04-11
IL86577A (en) 1993-06-10
WO1988009797A1 (en) 1988-12-15
JP2851288B2 (ja) 1999-01-27
CA1310902C (en) 1992-12-01
IL86577A0 (en) 1988-11-15
JPH04502143A (ja) 1992-04-16

Similar Documents

Publication Publication Date Title
EP0362278A4 (de) Autokrine beweglichkeitsfaktoren bei der diagnose und behandlung von krebs.
DE3765420D1 (en) Huelsengummifeder.
HK151195A (en) Composite cards
DE3769639D1 (en) Tuerschliesser.
GB8712594D0 (en) Taking up objects in medical field
EP0323522A4 (de) Kunstträne.
DE3850382D1 (en) Polyester-film.
JPS6431764A (en) 6-hydroxymethylene-branched 3-amino-4,5- dihydroxypiperidine
AU101058S (en) Card
GB8822532D0 (en) Improvements in forceps
EP0307752A3 (en) Poly(3-mono- and 3,5-disubstituted-4-acetoxystyrenes and 4-hydroxy-styrenes)and their use
JPS6468346A (en) Substituted anilinophenylthiourea, anilinophenylisothiourea and anilinophenylcarbodiimide
ZA889251B (en) 8,9-annelated-beta-carbolines and 8,9-annelated-3,4-dihydro-beta-carbolines
GB2190878B (en) Coin-holding card
GB8710916D0 (en) Badge press
GB8803520D0 (en) Improvements in ovens
IE872327L (en) Improvements in Rucksacks
GB2198155B (en) Improvements in knitting
GB2211382B (en) Improvements in swimfeeders
KR890006661Y1 (en) Telephone with card
GB8726577D0 (en) Arrangement in cabinet
GB8729028D0 (en) Improvements in signboards
CA58016S (en) Card
IE861587L (en) Glycosaminoglycan anti-thrombotics.
GB8607079D0 (en) Prize-generating cards

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19891030

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19900514

17Q First examination report despatched

Effective date: 19920508

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19920919